Global health experts are urging a rename of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The proposal is intended to better capture the condition’s wider hormonal and metabolic effects, rather than implying that ovarian cysts are the central issue. If adopted, it could reshape awareness, research framing, and patient understanding.
Actor Lisa Ray is tackling the stigma around menopause after her cancer treatment pushed her into early menopause, now backing NuHer, a midlife clinic offering integrated, science-backed support. Meanwhile, Proshort’s founder is turning generative AI into a real-time sales “super coach.” The startup claims it crossed $1M ARR within a year by analyzing sales conversations and workflows instantly.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
A low-profile pharma firm, Advent controlled-BSV, has drawn major investor attention after a turnaround that tripled its valuation in five years. Its focus on specialised women’s health products and a strong research pipeline have helped drive the momentum. Now, Mankind is set to acquire BSV in a $1.6 billion deal, putting the company’s next growth phase in the spotlight.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
